| Organic synthesis provides opportunities to transform drug discovery DC Blakemore, L Castro, I Churcher, DC Rees, AW Thomas, DM Wilson, ... Nature chemistry 10 (4), 383-394, 2018 | 1521 | 2018 |
| Catalytic in vivo protein knockdown by small-molecule PROTACs DP Bondeson, A Mares, IED Smith, E Ko, S Campos, AH Miah, ... Nature chemical biology 11 (8), 611-617, 2015 | 1476 | 2015 |
| Protac-induced protein degradation in drug discovery: breaking the rules or just making new ones? I Churcher Journal of medicinal chemistry 61 (2), 444-452, 2018 | 543 | 2018 |
| Lead‐oriented synthesis: a new opportunity for synthetic chemistry A Nadin, C Hattotuwagama, I Churcher Angewandte Chemie International Edition 51 (5), 1114-1122, 2012 | 473 | 2012 |
| Selected non-steroidal anti-inflammatory drugs and their derivatives target γ-secretase at a novel site: evidence for an allosteric mechanism D Beher, EE Clarke, JDJ Wrigley, ACL Martin, A Nadin, I Churcher, ... Journal of Biological Chemistry 279 (42), 43419-43426, 2004 | 261 | 2004 |
| Extended pharmacodynamic responses observed upon PROTAC-mediated degradation of RIPK2 A Mares, AH Miah, IED Smith, M Rackham, AR Thawani, J Cryan, ... Communications biology 3 (1), 140, 2020 | 227 | 2020 |
| Tau therapeutic strategies for the treatment of Alzheimer's disease I Churcher Current topics in medicinal chemistry 6 (6), 579-595, 2006 | 212 | 2006 |
| Modulating PCAF/GCN5 immune cell function through a PROTAC approach ZI Bassi, MC Fillmore, AH Miah, TD Chapman, C Maller, EJ Roberts, ... ACS Chemical Biology 13 (10), 2862-2867, 2018 | 176 | 2018 |
| A divergent synthetic approach to diverse molecular scaffolds: assessment of lead-likeness using LLAMA, an open-access computational tool I Colomer, CJ Empson, P Craven, Z Owen, RG Doveston, I Churcher, ... Chemical Communications 52 (45), 7209-7212, 2016 | 120 | 2016 |
| The novel γ secretase inhibitor N-[cis-4-[(4-chlorophenyl) sulfonyl]-4-(2, 5-difluorophenyl) cyclohexyl]-1, 1, 1-trifluoromethanesulfonamide (MRK-560) reduces amyloid plaque … JD Best, DW Smith, MA Reilly, R O’Donnell, HD Lewis, S Ellis, N Wilkie, ... The Journal of pharmacology and experimental therapeutics 320 (2), 552-558, 2007 | 107 | 2007 |
| A unified lead-oriented synthesis of over fifty molecular scaffolds RG Doveston, P Tosatti, M Dow, DJ Foley, HY Li, AJ Campbell, D House, ... Organic & biomolecular chemistry 13 (3), 859-865, 2015 | 95 | 2015 |
| Structural insights into PROTAC-mediated degradation of Bcl-xL C Chung, H Dai, E Fernandez, CP Tinworth, I Churcher, J Cryan, ... ACS Chemical Biology 15 (9), 2316-2323, 2020 | 88 | 2020 |
| 4-Substituted cyclohexyl sulfones as potent, orally active γ-secretase inhibitors I Churcher, D Beher, JD Best, JL Castro, EE Clarke, A Gentry, T Harrison, ... Bioorganic & Medicinal Chemistry Letters 16 (2), 280-284, 2006 | 87 | 2006 |
| Design and Synthesis of Highly Potent Benzodiazepine γ-Secretase Inhibitors: Preparation of (2S,3R)-3-(3,4- Difluorophenyl)-2-(4-fluorophenyl)-4- hydroxy-N-((3S)-1-methyl-2-oxo-5 … I Churcher, S Williams, S Kerrad, T Harrison, JL Castro, MS Shearman, ... Journal of medicinal chemistry 46 (12), 2275-2278, 2003 | 82 | 2003 |
| Synthesis and Demonstration of the Biological Relevance of sp3‐rich Scaffolds Distantly Related to Natural Product Frameworks DJ Foley, PGE Craven, PM Collins, RG Doveston, A Aimon, R Talon, ... Chemistry–A European Journal 23 (60), 15227-15232, 2017 | 78 | 2017 |
| The rise and rise of protein degradation: opportunities and challenges ahead SJ Hughes, A Testa, N Thompson, I Churcher Drug Discovery Today 26 (12), 2889-2897, 2021 | 76 | 2021 |
| γ-Secretase as a Therapeutic Target for the Treatment of Alzheimer's Disease I Churcher, D Beher Current pharmaceutical design 11 (26), 3363-3382, 2005 | 75 | 2005 |
| Optimization of a Series of RIPK2 PROTACs AH Miah, IED Smith, M Rackham, A Mares, AR Thawani, R Nagilla, ... Journal of Medicinal Chemistry 64 (17), 12978-13003, 2021 | 73 | 2021 |
| A new series of potent benzodiazepine γ-secretase inhibitors I Churcher, K Ashton, JW Butcher, EE Clarke, T Harrison, HD Lewis, ... Bioorganic & medicinal chemistry letters 13 (2), 179-183, 2003 | 73 | 2003 |
| In vivo characterization of Aβ (40) changes in brain and cerebrospinal fluid using the novel γ-secretase inhibitor N-[cis-4-[(4-chlorophenyl) sulfonyl]-4-(2, 5-difluorophenyl … JD Best, MT Jay, F Otu, I Churcher, M Reilly, P Morentin-Gutierrez, ... The Journal of pharmacology and experimental therapeutics 317 (2), 786-790, 2006 | 72 | 2006 |
